Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 66, Issue 3, Pages 486-493Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2010.12.038
Keywords
actinic keratosis; ingenol mebutate gel; mechanism of action; neutrophil; neutrophil-mediated antibody-dependent cellular cytotoxicity; protein kinase C; rapid lesion necrosis
Categories
Funding
- GlaxoSmithKline
- Novartis
- Merck
- Amgen
- Abbott
- Graceway
- Galderma
- Astellas
- Inhibitex
- Stiefel
- Eli Lilly and Company
- LEO Pharma
Ask authors/readers for more resources
Current topical agents for field therapy of actinic keratoses have single mechanisms of action and must be applied for weeks. Ingenol mebutate gel, a novel drug for field therapy of actinic keratoses, appears to have a dual mechanism of action: (1) rapid lesion necrosis and (2) specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Because of the rapid destruction of actinic keratosis lesions after application of ingenol mebutate gel, treatment is necessary for only 2 or 3 days. The subsequent immune-mediated response targets any residual dysplastic epidermal cells. This dual mechanism of action should provide efficacy equivalent to that of current topical agents with a substantially shorter treatment period. (J Am Acad Dermatol 2012;66:486-93.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available